Detail akcie GRI Bio Rg online

Business Summary: GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, GRI Bio Inc revenues was not reported. Net loss applicable to common stockholders increased 18% to $12M. Higher net loss reflects Research & Development Expense increase of 79% to $6.7M (expense), Stock-based Compensation in SGA increase from $148K to $707K (expense), Selling, General & Administrative Expn increase of 3% to $4.5M (expense).